We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cemiplimab

News List

Cemiplimab Prolongs Survival in Recurrent Cervical Cancer drugs.com
February 10, 2022
For patients with recurrent cervical cancer after first-line platinum-containing chemotherapy, survival is significantly longer with cemiplimab....
EU reviews for Sanofi’s Dupixent, cemiplimab pharmatimes
July 19, 2018
European regulators have agreed to review Sanofi and Regeneron’s Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma.
Sanofi and Regeneron announce that cemiplimab (REGN2810) has received FDA Breakthrough Therapy desig worldpharmanews
September 11, 2017
Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC)
FDA grants Breakthrough designation to Cemiplimab for CSCC europeanpharmaceuticalreview
September 11, 2017
Cemiplimab receives FDA Breakthrough Therapy Designation for advanced cutaneous squamous cell carcinoma…